Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer

被引:5
作者
Carbognin, Luisa [1 ]
Sperduti, Isabella [2 ]
Brunelli, Matteo [3 ]
Marcolini, Lisa [3 ]
Nortilli, Rolando [1 ]
Pilotto, Sara [1 ]
Zampiva, Ilaria [1 ]
Merler, Sara [1 ]
Fiorio, Elena [1 ]
Filippi, Elisa [1 ]
Manfrin, Erminia [2 ]
Pellini, Francesca [4 ]
Bonetti, Franco [2 ]
Pollini, Giovanni Paolo [3 ]
Tortora, Giampaolo [1 ]
Bria, Emilio [1 ]
机构
[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Ple LA Scuro 10, I-37124 Verona, Italy
[2] Regina Elena Inst Canc Res, Biostat, Rome, Italy
[3] Univ Verona, Azienda Osped Univ Integrata, Dept Pathol & Diagnost, I-37100 Verona, Italy
[4] Univ Verona, Azienda Osped Univ Integrata, Dept Surg & Oncol, Chirurg A, I-37100 Verona, Italy
关键词
Lobular; Breast cancer; Ki67; ADJUVANT CHEMOTHERAPY; CARCINOMA; THERAPY; KI-67; BENEFIT; MARKER;
D O I
10.1186/s13046-016-0325-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this analysis was to investigate the potential impact of Ki67 assay in a series of patients affected by early stage invasive lobular carcinoma (ILC) undergone surgery. Methods: Clinical-pathological data were correlated with disease-free and overall survival (DFS/OS). The maximally selected Log-Rank statistics analysis was applied to the Ki67 continuous variable to estimate appropriate cut-offs. The Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was performed to assess the interaction between 'pure' or 'mixed' histology ILC and Ki67. Results: At a median follow-up of 67 months, 10-years DFS and OS of 405 patients were 67.8 and 79.8 %, respectively. Standardized Log-Rank statistics identified 2 optimal cut-offs (6 and 21 %); 10-years DFS and OS were 75.1, 66.5, and 30.2 % (p = 0.01) and 84.3, 76.4 and 59 % (p = 0.003), for patients with a Ki67 < 6 %, between 6 and 21 %, and > 21 %, respectively. Ki67 and lymph-node status were independent predictor for longer DFS and OS at the multivariate analysis, with radiotherapy (for DFS) and age (for OS). Ki67 highly replicated at the internal cross-validation analysis (DFS 85 %, OS 100 %). The STEPP analysis showed that DFS rate decreases as Ki67 increases and those patients with 'pure' ILC performed worse than 'mixed' histology. Conclusions: Despite the retrospective and exploratory nature of the study, Ki67 was able to significantly discriminate the prognosis of patients with ILC, and the effect was more pronounced for patients with 'pure' ILC.
引用
收藏
页数:9
相关论文
共 31 条
[1]   Ki67-no evidence for its use in node-positive breast cancer [J].
Andre, Fabrice ;
Arnedos, Monica ;
Goubar, Aicha ;
Ghouadni, Amal ;
Delaloge, Suzette .
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) :296-301
[2]   Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome [J].
Arpino, G ;
Bardou, VJ ;
Clark, GM ;
Elledge, RM .
BREAST CANCER RESEARCH, 2004, 6 (03) :R149-R156
[3]   Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer [J].
Bria, Emilio ;
Di Modugno, Francesca ;
Sperduti, Isabella ;
Iapicca, Pierluigi ;
Visca, Paolo ;
Alessandrini, Gabriele ;
Antoniani, Barbara ;
Pilotto, Sara ;
Ludovini, Vienna ;
Vannucci, Jacopo ;
Bellezza, Guido ;
Sidoni, Angelo ;
Tortora, Giampaolo ;
Radisky, Derek C. ;
Crino, Lucio ;
Cognetti, Francesco ;
Facciolo, Francesco ;
Mottolese, Marcella ;
Milella, Michele ;
Nistico, Paola .
ONCOTARGET, 2014, 5 (22) :11054-11063
[4]   FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma [J].
Brunello, Eleonora ;
Brunelli, Matteo ;
Bogina, Giuseppe ;
Calio, Anna ;
Manfrin, Erminia ;
Nottegar, Alessia ;
Vergine, Marco ;
Molino, Annamaria ;
Bria, Emilio ;
Massari, Francesco ;
Tortora, Giampaolo ;
Cingarlini, Sara ;
Pedron, Serena ;
Chilosi, Marco ;
Zamboni, Giuseppe ;
Miller, Keith ;
Martignoni, Guido ;
Bonetti, Franco .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
[5]   Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].
Cheang, Maggie C. U. ;
Chia, Stephen K. ;
Voduc, David ;
Gao, Dongxia ;
Leung, Samuel ;
Snider, Jacqueline ;
Watson, Mark ;
Davies, Sherri ;
Bernard, Philip S. ;
Parker, Joel S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750
[6]   Lobular breast cancer: molecular basis, mouse and cellular models [J].
Christgen, Matthias ;
Derksen, Patrick W. B. .
BREAST CANCER RESEARCH, 2015, 17
[7]   Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].
Coates, A. S. ;
Winer, E. P. ;
Goldhirsch, A. ;
Gelber, R. D. ;
Gnant, M. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546
[8]   High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer [J].
Criscitiello, Carmen ;
Disalvatore, Davide ;
De Laurentiis, Michele ;
Gelao, Lucia ;
Fumagalli, Luca ;
Locatelli, Marzia ;
Bagnardi, Vincenzo ;
Rotmensz, Nicole ;
Esposito, Angela ;
Minchella, Ida ;
De Placido, Sabino ;
Santangelo, Michele ;
Viale, Giuseppe ;
Goldhirsch, Aron ;
Curigliano, Giuseppe .
BREAST, 2014, 23 (01) :69-75
[9]   Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes [J].
Cristofanilli, M ;
Gonzalez-Angulo, A ;
Sneige, N ;
Kau, SW ;
Broglio, K ;
Theriault, RL ;
Valero, V ;
Buzdar, AU ;
Kuerer, H ;
Buccholz, TA ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :41-48
[10]   Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients [J].
de Azambuja, E. ;
Cardoso, F. ;
de Castro, G., Jr. ;
Colozza, M. ;
Mano, M. S. ;
Durbecq, V. ;
Sotiriou, C. ;
Larsimont, D. ;
Piccart-Gebhart, M. J. ;
Paesmans, M. .
BRITISH JOURNAL OF CANCER, 2007, 96 (10) :1504-1513